A new target for improving osteoporosis with eldecalcitol—Mini-modeling bone formation / 中华内分泌代谢杂志

As a basic anti-osteoporosis drug, active vitamin D mainly promotes intestinal absorption of calcium and phosphorus, inhibits the release of parathyroid hormone, and maintains normal blood calcium and phosphorus levels, thus ensuring bone health. Eldecalcitol(ED-71), a novel derivative of active vitamin D, was approved for clinical treatment of osteoporosis in Japan in 2011. Eldecalcitol not only improves intestinal calcium absorption and inhibits osteoclast differentiation, but also effectively promotes "mini-modeling" bone formation-focal bone formation that is independent of osteoclastic bone resorption, elevating trabecular continuity and increasing the thickness of weak trabeculae, thereby repairing the microinjury of bone tissue.